Table 1. Baseline characteristics of patients enrolled in the patient navigator intervention.
| Characteristics | N = 107 |
|---|---|
| Female–N (%) | 100 (93.5) |
| Mean age, years (±SD) | 54.7 (±16.7) |
| Race–N (%) | |
| White | 75 (70.1) |
| Asian | 2 (1.9) |
| Black/African American | 6 (5.6) |
| Not reporteda | 24 (22.4) |
| Ethnicity–N (%) | |
| Non-Hispanic | 83 (77.6) |
| Hispanic | 19 (17.8) |
| Not reported | 5 (4.7) |
| Primary Language–N (%) | |
| English | 92 (86.0) |
| Spanish | 13 (12.2) |
| Bilingual | 2 (1.9) |
| Insurance Status–N (%) | |
| Medicaid | 14 (13.1) |
| Medicare | 35 (32.7) |
| Private | 57 (53.3) |
| Other | 1 (0.9) |
| Education–N (%) | |
| Graduated College or graduate school | 50 (46.7) |
| Some College | 24 (22.4) |
| High School/GED | 18 (16.8) |
| Some High School | 3 (2.8) |
| 8th Grade or Less | 3 (2.8) |
| Decline/Unknown/Not reported | 9 (8.4) |
| Rheumatic Disease–N (%) | |
| Rheumatoid Arthritis | 87 (81.3) |
| Lupus | 7 (6.5) |
| Mixed Connective Tissue Disease | 4 (3.7) |
| Other | 9 (8.4) |
| DMARD Useb –N (%) | |
| Methotrexate | 56 (52.3) |
| Sulfasalazine | 11 (10.3) |
| Tofacitinib | 7 (6.5) |
| Hydroxychloroquine | 40 (37.4) |
aMost patients of Hispanic ethnicity did not report race
bCategories are not mutually exclusive; patients received more than one DMARD simultaneously